Trial record 1 of 1 for:    13-AT-0143
Previous Study | Return to List | Next Study

Brain Response to Pain Control in People With Chronic Pain

This study is currently recruiting participants.
Verified February 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Center for Complementary and Alternative Medicine (NCCAM) )
ClinicalTrials.gov Identifier:
NCT01878019
First received: June 12, 2013
Last updated: March 14, 2014
Last verified: February 2014
  Purpose

Background:

- Researchers want to look at how the brain responds to painful stimulations. They also want to see if these responses are different in people with and without chronic pain. To test the brain s response, they will use a chemical called naloxone. Naloxone is used to treat overdoses of painkilling drugs like morphine. It may be able to block the effect of a pain-relieving cream. Researchers will apply a pain-relieving cream to a person s lower leg and look at the results of sensitivity tests with either naloxone or a placebo. This study will compare the results from people with chronic pain (like fibromyalgia) to those of people without chronic pain.

Objectives:

- To look at the brain s response to pain in people with and without chronic pain.

Eligibility:

  • Individuals at least 18 years of age who have fibromyalgia.
  • Healthy volunteers at least 18 years of age.

Design:

  • This study will involve a screening visit and two testing visits. The testing visits will be about a week apart.
  • Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. After the screening participants will be administered several questionnaires about their personality, and their thoughts and feelings.
  • At the first visit, participants will try out the magnetic resonance imaging (MRI) scan before using it at the next visit. They will then have the painkilling cream applied on one part of their lower leg and a normal moisturizing cream on the other part of their lower leg. They will have heat pulses on these skin areas and rate the pain.
  • At the second visit, participants will have tests in the MRI scanner. The heat pulse tests will be repeated after an infusion of either naloxone or a placebo....

Condition
Pain

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Mechanisms of Pain Control in Chronic Pain Patients

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Pain Perception [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 115
Study Start Date: May 2013
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Different pain reducing drugs work in different ways to reduce pain. Many drugs, including morphine and codeine, reduce pain by binding to opiate receptors in the brain. Another chemical, naloxone, can block the effect of these drugs. In this study, we are looking at brain responses to a pain-relieving cream and whether naloxone blocks the effect of the cream. We will compare the results of people with chronic pain (fibromyalgia) to those of people without chronic pain.

Design:

The study compares MRI response to painful stimulation between people with fibromyalgia and healthy volunteers under two conditions: 1) naloxone, 2) placebo.

Outcome measures: Pain ratings and pain-related MRI responses are compared between people with fibromyalgia and healthy volunteers

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Inclusion Criteria for Patients:

  1. Patient must be greater than or equal to 18 years of age.
  2. Patient must be right-handed.
  3. Patient must be able to comprehend English.
  4. Patient must be able to provide written informed consent.
  5. Patient must have had chronic widespread pain for at least one year prior to participation with an average daily intensity at least 4 out of 10.

Inclusion Criteria for Healthy Controls:

  1. Healthy control must be greater than or equal to 18 years of age
  2. Healthy control must be right-handed.
  3. Healthy control must be able to comprehend English.
  4. Healthy control must be able to provide written informed consent.

EXCLUSION CRITERIA:

Exclusion criteria for patients:

  1. Patient is unable to comply with study procedures or follow-up visits
  2. Patient smokes more than 10 cigarettes of nicotine per week.
  3. Patient uses recreational drugs.
  4. Female patient consumes more than 7 half-pint beers, 7 6-oz glasses of wine or 7 1-oz shots of spirits (or equivalent) per week, and male patient consumes 14 such drinks per week. Further, patient consumes more than 5 drinks at one time.
  5. Patient is pregnant or breastfeeding.
  6. Patient has a major medical condition, such as kidney, liver, cardiovascular, neurological or current psychiatric condition.
  7. Patient has currently or has had in the past major depression, bipolar disorder, psychosis or suicide attempts.
  8. Patient has metal in his/her body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have.
  9. Patient is uncomfortable in small closed spaces (has claustrophobia) so that he/she would feel uncomfortable in the MRI machine.
  10. Patient cannot lie comfortably flat on his/her back for up to 75 minutes in the MRI scanner.
  11. Patient has allergies to topical treatment.
  12. Patient has a chronic pain condition other than FM.
  13. Patient has taken within the last two weeks opioids. Other medications used to treat fibromyalgia at the standard doses in the community can be taken. We will not ask participants to stop any medication to participate in the study.
  14. Patient has previously taken opioids for more than one month on a continual basis, within the last 6 months.
  15. Patient had seen study information on clinicaltrials.gov prior to September 23, 2013.
  16. Patients who decline to be audio and/or videotaped will be excluded from the qualitative interview component of the study.

Exclusion criteria for healthy controls:

  1. Healthy control is unable to comply with study procedures or follow-up visits
  2. Healthy control smokes more than 10 cigarettes of nicotine per week.
  3. Healthy control uses recreational drugs.
  4. Female healthy control consumes more than 7 half-pint beers, 7 6-oz glasses of wine or 7 1-oz shots of spirits (or equivalent) per week, and male healthy control consumes 14 such drinks per week. Further, healthy control consumes more than 5 drinks at one time.
  5. Healthy control is pregnant or breastfeeding.
  6. Healthy control has a major medical condition, such as kidney, liver, cardiovascular, neurological or current psychiatric condition.
  7. Healthy control has currently or has had in the past major depression, bipolar disorder, psychosis or suicide attempts.
  8. Healthy control has metal in his/her body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments,
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01878019

Contacts
Contact: Robin N Godwin, C.R.N.P. (301) 594-5731 robin.godwin@nih.gov
Contact: Mary C Bushnell, Ph.D. Not Listed bushnellmc@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: Mary C Bushnell, Ph.D. National Center for Complementary and Alternative Medicine (NCCAM)
  More Information

Additional Information:
Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Center for Complementary and Alternative Medicine (NCCAM) )
ClinicalTrials.gov Identifier: NCT01878019     History of Changes
Other Study ID Numbers: 130143, 13-AT-0143
Study First Received: June 12, 2013
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Pain
Placebo
Opiate Antagonist

ClinicalTrials.gov processed this record on April 22, 2014